Alembic Pharmaceuticals Ltd. News and Updates

Name: Latest research reports of Alembic Pharmaceuticals Ltd. authored by Karvy and published by - Trendlyne research reports.
Item: Alembic Pharmaceuticals Ltd.
Rating: 3
Author: Karvy

Keep track of all breaking news on Alembic Pharmaceuticals Ltd. from all sources in a single place.

Load latest

Alembic Pharmaceuticals Ltd.

24 Oct 2019, 09:59PM

921.90

0.18%

Company news: Alembic Pharmaceuticals

Business Line

Alembic Pharmaceuticals's joint venture Aleor Dermaceuticals has received an approval from the US Food & Drug Administration for its Abbreviated N

Alembic Pharmaceuticals Ltd. is trading below all available SMAs

Alembic Pharmaceuticals Ltd.

22 Oct 2019

921.90

0.18%

Company news | Alembic Pharmaceuticals

Business Line

Alembic Pharmaceuticals on Tuesday announced that its joint venture Aleor Dermaceuticals Ltd (Aleor) has received approval from the USFDA for its ANDA

Alembic Pharmaceutic.. has an average target of 1001.00 from 4 brokers.

Alembic Pharmaceuticals Ltd.

04 Oct 2019

921.90

0.18%

Alembic Pharmaceuticals (547):Buy

Business Line

The stock of Alembic Pharma, which has been trading in the band between 500 and 550 for the past three months, broke out of the range as the company

Alembic Pharmaceutic.. has an average target of 1001.00 from 4 brokers.

Alembic Pharma JV gets USFDA nod for plaque psoriasis treatment drug

Business Line | 04 Oct 2019

Alembic Pharmaceuticals Ltd.

31 Jul 2019

921.90

0.18%

Alembic Pharmaceuticals: Lower revenue growth due to muted performance in domestic formulations and ROW market

Hold: Alembic Pharmaceuticals Ltd.

Target

Karvy

In Q1FY20, total revenues of Alembic Pharma increased by 10% YoY to Rs 9.5 bn (below our estimates Rs 9.8 bn).

Alembic Pharmaceuticals Ltd. is trading below all available SMAs

Alembic Pharmaceuticals Ltd.

30 Jul 2019

921.90

0.18%

Alembic Pharma (1QFY20): Unappealing, ex-US. Maintain NEUTRAL

Neutral: Alembic Pharmaceuticals Ltd.

Target

HDFC Securities

1QFY20's sharp improvement in operating performance was driven by short-term opportunities in the US, which will not persist. Sustainable growth relies upon approvals for lucrative onco-injectables and derma products, which will reflect in revenues only by FY22E. Meanwhile in India, the co is consistently underperforming the broader market. Hence, we lack visibility on revenue growth above 13% CAGR over FY19-21E. Additionally, incremental stress on margins (-100bps over FY19-21E) will restrict PAT CAGR to 11%. Valuations, too, remain unsupportive at 21.1/16.8x FY20/21E P/E. We maintain NEUTRAL on ALPM following a miss on our revenue estimates, while profitability was higher than expectation. Growth across segments was muted, barring the US. Our TP is unchanged at Rs 570 (18x FY21E EPS).

Alembic Pharmaceuticals Ltd. is trading below all available SMAs

Alembic Pharmaceuticals Ltd.

30 Jul 2019

921.90

0.18%

Alembic Pharmaceuticals

Sell: Alembic Pharmaceuticals Ltd.

Recommendation Target

ICICI Securities Limited

Specialty contribution in the domestic branded space increased to 63% in FY19 from 54% in FY14. With ~3900 MRs at its disposal, the company enjoys a wide reach among doctors. We expect the specialty segment to remain a key driver for domestic market on the back of aggressive product launches and constant addition of new speciality segments & sub-segments....